News
5h
Zacks.com on MSNGSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook RaiseGSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...
The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results